Testosterone Prescriptions for Women Rise 146% Despite No FDA-Approved Female Formulations

The surge reflects growing clinician adoption of testosterone for hypoactive sexual desire disorder in postmenopausal women, where organizations including the Menopause Society endorse therapy based on randomized trials showing improved desire and satisfaction. However, no products carry FDA labeling for female use, forcing compounding or male-formulation adjustments that trigger insurance rejections and dosage inconsistencies at pharmacies. Stephanie Faubion of Mayo Clinic notes testosterone levels decline with age rather than menopause itself, with evidence limited to sexual function and absent for fatigue, mood, or muscle mass. FDA's September 17 call for new manufacturer studies highlights the regulatory gap, while some clinicians continue broader off-label prescribing despite guideline cautions.